Mylan Claims Another Victory Over Teva on Copaxone Patents

International Pharmaceutical Regulatory Monitor
A A
A U.K. court ruled for Mylan in its challenge to Teva’s patents on the long-acting version of Teva’s blockbuster multiple sclerosis drug.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor